ADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM®

Aug 22, 2019

ADMA Biologics Reports Second Quarter and First Half 2019 Financial Results

Aug 8, 2019

ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®

Jul 8, 2019

ADMA Biologics to Present at Upcoming Investor Conferences

May 29, 2019

ADMA Biologics Announces Closing of $51.75 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

May 21, 2019

ADMA Biologics Announces Pricing of Public Offering of Common Stock

May 17, 2019

ADMA Biologics Announces Proposed $45 Million Public Offering of Common Stock

May 15, 2019

FDA Approves Prior Approval Supplement for BIVIGAM®

May 10, 2019

ADMA Biologics Reports First Quarter 2019 Financial Results

May 8, 2019

ADMA Biologics Elects to Draw-Down $27.5 Million in Capital from Existing Perceptive Advisors Credit Agreement

May 3, 2019